Post by Novartis

Novartis delivered strong growth in priority brands and recent launches during Q1 2026, while US generic erosion weighed on results as expected. We continued to advance our pipeline with innovation milestones, a completed acquisition and announced early-stage deals. With the momentum we are seeing across the business, we remain on track to deliver our full year guidance. Link to press release: https://lnkd.in/gCaPwCtQ #NVSQ126